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Abstract: The distinct properties of allo-reactive T-cell repertoires are not well understood. To
investigate whether auto-reactive and allo-reactive T-cell repertoires encoded distinct properties,
we used dextramer enumeration, enrichment, single-cell T-cell receptor (TCR) sequencing and
multiparameter analysis. We found auto-reactive and allo-reactive T-cells differed in mean ex
vivo frequency which was antigen dependent. Allo-reactive T-cells showed clear differences in TCR
architecture, with enriched usage of specific T-cell receptor variable (TRBJ) genes and broader use of T-
cell receptor variable joining (TRBJ) genes. Auto-reactive T-cell repertoires exhibited complementary
determining regions three (CDR3) lengths using a Gaussian distribution whereas allo-reactive T-cell
repertoires exhibited distorted patterns in CDR3 length. CDR3 loops from allo-reactive T-cells showed
distinct physical-chemical properties, tending to encode loops that were more acidic in charge. Allo-
reactive T-cell repertoires differed in diversity metrics, tending to show increased overall diversity
and increased homogeneity between repertoires. Motif analysis of CDR3 loops showed allo-reactive
T-cell repertoires differed in motif preference which included broader motif use. Collectively, these
data conclude that allo-reactive T-cell repertoires are indeed different to auto-reactive repertoires
and provide tangible metrics for further investigations and validation. Given that the antigens
studied here are overexpressed on multiple cancers and that allo-reactive TCRs often show increased
ligand affinity, this new TCR bank also has translational potential for adoptive cell therapy, soluble
TCR-based therapy and rational TCR design.
Keywords: T-cell; T-cell receptor; T-cell repertoire; T-cell alloreactivity
1. Introduction
Many questions remain on the distinct properties of allo-reactive T-cells [1]. Despite
the fact that allo-reactive T-cells are an established clinical correlate of graft rejection,
knowledge of the precise molecular characteristics of this T-cell repertoire are largely
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unknown. Initial T-cell receptor (TCR) repertoire studies have shown TCR repertoire
structure correlates with rejection [2,3], cancer protection post-transplant [4], pathogen
infection post-transplant [3], and high TCR avidity [5].
Three models of alloreactivity have been proposed [6]. First, is that allo-reactive TCRs
recognise foreign human leukocyte antigen (HLA) molecules directly, with the peptide
(p) being irrelevant, termed the “promiscuous model”. Second, is that allo-reactive TCRs
rearrange their CDR3 loops to recognise promiscuous shapes, termed the “degenerate
model”. Third, is that allo-reactive TCRs bind both peptide and HLA in conventional form,
making small changes in the contact interface that dramatically modify binding affinity,
termed the “polyspecific model”. Massing functional, biophysical, and structural evidence
supports the polyspecific model with allo-reactive TCRs binding both HLA and peptide in
a conventional manner, often through molecular mimicry binding “hotspot” regions [7–10].
Solid-organ transplant (SOT) and hematopoietic stem-cell transplantation (HSCT)
rejection can be controlled using T-cell suppressing drugs such as cyclosporine, corticos-
teroids, rapamycin or infusions with T-cell suppressing monoclonal antibodies. However,
these life-long T-cell suppressing drug regiments come with increased risk of infection,
cardiovascular disease and cancer [11]. Acute graft rejection may occur between one-week
and three-weeks post-transplant. Chronic rejection can occur over many years. It is thought
that chronic rejection can be triggered by innocuous infections, which activate allo-reactive
memory T-cells that damage host tissue [12]. Many SOT rejection episodes involve T
cell-mediated damage, but these episodes do not always destroy grafts [13,14].
T-cell mediated HSCT rejection comprises three modalities. First, T-cells can recognise
host pHLA directly, termed the “direct alloresponse”. Second, T-cell-derived peptide
fragments presented by donor HLA can be recognised, termed the “indirect alloresponse”.
Third, T-cells can recognise pMHC molecules that have been transferred from donor cells
to recipient cells, termed the “semidirect alloresponse” [14].
Currently, structural, biophysical, mutational, and functional analysis of auto-reactive
and allo-reactive TCRs and pHLAs agrees with a conventional top-down docking mode,
where both the germline loops of the TCR and the somatic complementary determin-
ing regions three (CDR3) loops contact both the peptide and HLA. This docking occurs
in a roughly diagonal manner with binding affinities between KD = 0.3 µM and above
1 mM [9,10,15,16]. However, this conventional docking mode can sometimes vary [17].
The mouse major histocompatibility complex (MHC-I) restricted 2C TCR binds its auto-
reactive ligand at KD = 83–85 µM, approximately 40-fold weaker its allo-reactive ligands
at KD = 2–3 µM [10,18,19]. In humans, the antiviral LC13 TCR binds its auto-reactive
ligand at KD = 10 µM [16], approximately 10-fold weaker than its allo-reactive ligand
at KD = 1 µM [17]. The structures of these complexes show they bind both HLA and
peptide with conventional footprints [17–23]. Of additional interest is the auto-reactive
MHC-II-restricted mouse TCR YAe62 can also bind a MHC-I ligand [24]. This TCR tran-
scends MHC-restriction dogma. The same phenomenon has been shown in humans, with
a virus-specific HLA-I-restricted TCR being allo-reactive with an HLA-II-restricted lig-
and [25]. TCRs are also known to recognise different antigens presented by different HLA-I
alleles [26,27]. In general, the polyspecific model appears to best conform with alloreactiv-
ity [22], with the peptide being the focus of affinity variation [28] through increased atomic
contacts [22]. However, TCR/pMHC structural correlations or multimer correlations have
not yet been explicitly linked with graft acceptance or rejection in humans.
In this study, we aimed to investigate two gaps in knowledge. First, was to deter-
mine whether antigen-specific precursors differed in frequency between auto-reactive and
allo-reactive individuals. Second, was to determine if T-cell repertoires could be separated
into auto-reactive and allo-reactive groups when quantitating TCR gene preference, TCR
gene pairings, CDR3 length, CDR3 physiochemical-properties, CDR3 diversity metrics and
CDR3 motifs. Here, we used HLA-0201 dextramers bearing four different immunogenic
tumour associated antigens (TAAs). The first was IMNDMPIYM (herein referred to as IMN)
derived from the transmembrane receptor EphA2 and overexpressed in prostate, breast,
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colon, gastric cancers, and metastatic melanoma [29–31]. Second, was FLCMKALLL (herein
referred to as FLC) [32] derived from the android receptor ligand-binding domain protein
and overexpressed in prostate cancer, breast cancers and hepatocellular carcinoma [33–35].
Third, was KVAELVHFL (herein referred to as KVA) derived from the MAGE-A3 pro-
tein and overexpressed in prostate, breast, and esophageal cancers [36–38]. Fourth, was
YLEPGPVTV (herein referred to as YLE) derived from the gp100 protein, which is found
in premelanosomal pigmented cells and the retina and overexpressed in numerous can-
cers, including prostate cancer [38]. In this study, HLA-0201+ donors are referred to as
auto-reactive and HLA-0201− donors are referred to as allo-reactive.
2. Results
2.1. Antigen-Specific T-Cells Show Different Frequencies between Auto-Reactive and
Allo-Reactive Settings
Previous experience enumerating and sorting extremely low-frequency T-cell popu-
lations in cord and adult blood [39] has shown us success requires; (i) the use of a bright
fluorochrome on the dextramer [40]; (ii) the use of freshly made dextramers which increases
brightness 13-to-50-fold, compared with other multimers [39,41]); (iii) the use of the protein
kinase inhibitor dasatinib which prevents TCR internalisation, activation-induced cell
death [42] and increases multimer brightness up to 50-fold [40]; (iv) cell dumping using
LIVE/DEAD, CD14, CD16 and CD19 [40] and; (v) a decreased sorter flow rate which
minimises the abort rate of dextramer+ cells. An important variable in this protocol is the
functional avidity of the T-cell population under investigation, which derives from the
physiology and activation status of the cells.
Using flow cytometry, we found that IMN- and FLC-specific T-cells had variable
mean frequencies across auto-reactive and allo-reactive populations (Figure 1A,B), YLE-
specific T-cells had a significantly higher mean frequency (p ≤ 0.0002) in auto-reactive
populations than allo-reactive populations (Figure 1C). KVA-specific T-cells exhibited
a higher mean frequency when comparing auto-reactive and allo-reactive populations
(Figure 1D). Collectively, the frequency hierarchy was FLC > IMN > KVA > YLE, ranging
from a mean of 0.004−0.06% of CD8+ T-cells. Examples of dextramer plots from ex vivo
samples are shown (Figure 1E–H), revealing the low percentages of these cells in the blood.
Examples of samples that have been sorted twice for purity (and further single-cell sorting)
are also shown (Figure 1I,J), highlighting that antigen-specific T-cells can be reliably isolated
and enriched from both auto-reactive and allo-reactive settings.
2.2. The IMN Allo-Reactive T-Cell Repertoire Exhibits Expanded TRBV Gene Usage and
Unconventional CDR3 Loop Length
We next performed single-cell sorting and TCR analysis on IMN- and FLC-specific
T-cells given that these dextramers had the highest mean fluorescence intensity (MFI)
of the dextramer set and had the highest frequencies in the blood. These features help
confirm precise sorting and provided confidence in downstream analysis. IMN-specific
TCR sequences were then pooled and normalised by clonotype count and appearance.
Differences in TRBV usage was highly significant between cohorts showing 77% of total
variation by two-way ANOVA (p ≤ 0.0001) (Figure 2A). Here, 27-of-30 (90%) TRBV genes
were deployed in allo-reactive repertoires versus 19-of-30 (63%) in auto-reactive repertoires.
The total variation in TRBJ usage was also highly significant between cohorts at 92% by
two-way ANOVA (p ≤ 0.0001) (Figure 2B). There was also a distinct difference in CDR3
length between repertoires with the allo-reactive repertoire not exhibiting a conventional
Gaussian distribution in CDR3 length, which typically shows a peak at 15 residues in
length. The CDR3 length variation between cohorts was 76% and significant by two-way
ANOVA (p ≤ 0.025) (Figure 2C). Interestingly, allo-reactive TCRs tended to encode shorter
CDR3 loops. Here, in allo-reactive CDR3 loops, 61% of the repertoire was under 13 residues
in length versus 18% in the auto-reactive cohort. There were no significant differences in
TRBD usage between auto-reactive (Figure 2D) and allo-reactive (Figure 2E) TCRs, with
the TRBD1*01 gene predominating in both cohorts.
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Figure 1. Different frequencies among dextramer populations in the blood for auto-reactive and allo-reactive T-cells.
Dextramers include (A) IMN, (B) FLC, (C) YLE and (D) KVA. Frequency of CD8+ cells is shown on the y-axis, and dextramer
frequencies from auto-reactive (green) and allo-reactive (orange) donors on the x-axis. Comparisons of IMN, FLC and KVA
cohorts were not significant. Frequencies from the YLE-specific cohorts were significantly different, with the auto-reactive
donors dominating. Examples of IMN (E), FLC (F), YLE (G) and KVA (H) dextramer staining ex vivo. Examples of
dual (sequential) dextramer sorting from an (I) auto-reactive repertoire and (J) allo-reactive repertoire using IMN. ns, no
significant; *** p ≤ 0.001.
Figure 2. Different IMN-specific T-cell repertoires between auto-reactive donors and allo-reactive donors. Bar charts
showing percentage use of (A) TRBV and (B) TRBJ preference from auto-reactive (green) versus allo-reactive (orange)
donors. (C) Line chart comparing percentage use of CDR3 length. (D,E) Pie charts comparing percentage use of the TRBD
genes. Pie charts showing clonotype frequencies in (F) three auto-reactive donors and (G) three allo-reactive donors. Each
slice represents a unique clonotype from the repertoire of a single donor. Unique clonotypes with multiple copies are shown
in red and unique clonotypes with a single copy are shown in grey. Percentages were determined by summing the total
clonotypes found within a single donor.
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We then compared total clonotype frequencies in three auto-reactive donors (Figure 2F)
and three allo-reactive donors (Figure 2G) by total abundance sampling. Here, three-of-
three auto-reactive donors exhibited multiple copies of an individual clonotype against
IMN, with frequencies up to 93% for a single clonotype in donor 1 (Figure 2F). Within
the allo-reactive donors, one-of-three individuals exhibited multiple copies of an individ-
ual clonotype against IMN, with a frequency of 16% for a single clonotype in donor 4
(Figure 2G).
2.3. IMN-Specific T-Cell Repertoires Exhibit Divergent TCR Gene Pairing
IMN-specific T-cell repertoires were next compared for TRBV/JTRBJ and TRAV/TRAJ
pairing bias using normalised counts by abundance and chord diagram analysis (Figure 3).
In the auto-reactive repertoire, the large unique multiple copy clonotype from auto-reactive
donor 1 (TRAV12-2/TRBV5-4) was observed along with preferential pairing of TRBV7-9
and JTRBJ2-1 for TRB genes and TRAV12-2 and TRAJ27 for the TRA genes. TCR gene
pairings in the allo-reactive repertoire were much more complex. However preferential
pairings of TRBV7-9 and TRBV2 with JTRBJ2-7 were observed for the TRB genes and
TRAV12-2 and TRAJ39 for the TRV genes. More TRAJ genes were utilized in the allo-
reactive repertoire compared with the auto-reactive repertoire.
Figure 3. Chord diagrams of IMN-specific (A) auto-reactive (green) and (B) allo-reactive (orange)
repertoires showing TRBV-TRBJ and TRAV-TRVJ pairings. The size of the connections represents an
increased frequency of appearance.
2.4. The FLC-Specific Allo-Reactive T-Cell Repertoire Exhibits Divergent TRBV and TRBJ Gene
Usage, Unconventional CDR3 Loop Length and Common Multiple Copy Clonotypes
Like the IMN-specific repertoires, FLC-specific TCR sequences were also pooled and
normalised by clonotype count and appearance. Differences in TRBV usage were highly
significant showing 73.86% between cohorts by two-way ANOVA (p ≤ 0.005) (Figure 4A).
Differences in TRBJ usage were also significant showing 80% variation by two-way ANOVA
(p ≤ 0.016) (Figure 4B). Akin to allo-reactive IMN repertoire, the FLC-specific allo-reactive
Int. J. Mol. Sci. 2021, 22, 1625 6 of 16
repertoire did not exhibit a Gaussian distribution in CDR3 length showing 90% variation
compared to the auto-reactive repertoire by two-way ANOVA (p ≤ 0.0001) (Figure 4C).
Allo-reactive CDR3 sequences were shorter than auto-reactive sequences but not to the
same degree as seen in the IMN system, with 37% and 34% of total sequences, respectively
being under 13 residues in length. There were no significant differences in TRBD usage
between auto-reactive (Figure 4D) and allo-reactive (Figure 4E) TCRs, with the TRBD1*01
gene predominating in both cohorts.
When examining the total clonotype frequencies per donor, two-of-three auto-reactive
donors showed unique clonotypes with multiple copies (Figure 4F) versus three-of-three in
allo-reactive donors (Figure 4G). Donor 12 showed the largest unique clonotype frequency
of 46%. These multiple copy clonotypes in FLC allo-reactive donors are different to the
IMN system which were comprised of single unique clonotypes per donor.
Figure 4. Different FLC-specific T-cell repertoires between auto-reactive and allo-reactive donors. Bar charts showing
percentage use of (A) TRBV and (B) TRBJ preference from auto-reactive (green) versus allo-reactive (orange) donors. (C)
Line chart comparing percentage use of CDR3 length. (D,E) Pie charts comparing percentage use of the TRBD genes.
Pie charts showing clonotype frequencies in (F) three auto-reactive donors and (G) three allo-reactive donors. Each slice
represents a unique clonotype from the repertoire of a single donor. Unique clonotypes with multiple copies are shown
in red and unique clonotypes with a single copy are shown in grey. Percentages were determined by summing the total
clonotypes found within a single donor.
2.5. FLC-Specific T-Cell Repertoires Exhibit Divergent TCR Gene Pairing
FLC-specific T-cell repertoires were next compared for TRBV/TRBJ and TRAV/TRAJ
pairing bias using normalised counts by abundance and chord diagram analysis (Figure 5).
In the auto-reactive repertoire, we observed preferential pairing of TRBV20-1 and TRBJ2-5
for TRB genes and TRAV5 and TRAJ47 for the TRA genes. TCR gene pairings in the allo-
reactive repertoire were again more complex. However, preferential pairings of TRBV19
and TRBV2-1 were observed for the TRB genes and TRAV19 and TRAJ49 for the TRV genes.
Akin to the IMN system, more TRAJ genes were utilized in the allo-reactive repertoire
compared with the auto-reactive repertoire.
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Figure 5. Chord diagrams of FLC-specific (A) auto-reactive (green) and (B) allo-reactive (orange)
repertoires showing TRBV-TRBJ and TRAV-TRVJ pairings. The size of the connections represents an
increased frequency of appearance.
2.6. T-Cells Exhibit Divergent CDR3 Physical-Chemical Properties between Auto-Reactive and
Allo-Reactive Repertoires
We next examined the physical-chemical properties of the CDR3 loops in the IMN- and
FLC-specific repertoires by pooling the sequences based on appearance. In both systems,
all metrics measured were different between auto-reactive and allo-reactive repertoires
(Figure 6) and combined, showed 95% variance by two-way ANOVA (p ≤ 0.0001). In
the IMN cohorts, auto-reactive CDR3 were more hydrophobic (p ≤ 0.04) and had higher
mean grand average of hydropathicity index (GRAVY) scores showing these receptors
had a low dielectric constant to water. Auto-reactive IMN CDR3 also had higher average
molecular weights (Mw) (p = 0.008) and average monoisotopic Mw (p ≤ 0.008), showing
that these CDR3 were longer and/or have bulkier side chains. Auto-reactive IMN TCR also
had higher mean theoretical pI suggesting that these receptors were more basic in charge.
Interestingly, this pattern of hydrophobic, GRAVY, Mw and monoisotopic Mw metrics was
inverted in the FLC system, showing that the physical-chemical properties of CDR3 loops
are largely determined by antigen. Of note, was an increase in mean in theoretical pI in
auto-reactive FLC-specific receptors which matched the IMN system.
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Figure 6. Physical-chemical properties analysis of CDR3 loops between auto-reactive and allo-reactive TCRs. (A) IMN
CDR3 (green) and (B) FLC CDR3 loops (orange) were compared by hydrophobicity, GRAVY, Mw average, Mw monoisotopic
and theoretical pI scores. TCR were pooled and measured by appearance. * p ≤ 0.05, ** p ≤ 0.01.
2.7. T-Cells Exhibit Divergent CDR3 Diversity Metrics between Auto-Reactive and
Allo-Reactive Repertoires
We next quantitated and compared diversity metrics of IMN- and FLC-specific CDR3
loops from individual repertoires from auto-reactive and allo-reactive donors (Table 1).
While individual diversity metrics did not reach significance, likely due to the low numbers
of donors in each cohort (n = 3), the combined metrics explained 45% (p ≤ 0.0008) and 50%
(p ≤ 0.0001) of the variation between the IMN and FLC cohorts, respectively. Notably, the
same Log2 fold-change (Log2FC) patterns were observed in both IMN and FLC systems
suggesting these measures may be valid on an expanded donor analysis. The most heavily
weighted diversity measurements are shown, as are the Log2FC changes with increases
shown in blue decreases shown in red.
Using 12 formulas of diversity, we compared each system. Both IMN and FLC
repertoires showed that allo-reactive TCR had increased numbers of unique clonotypes per
individual (Menhinick index and Margalef Richness index), showed fewer multiple copy
clonotypes but when they were present, were more prevalent in the repertoire (Dominance
index and Gini coefficient). Allo-reactive TCR showed an overall increase in diversity
which factors both total unique clonotypes and unique clonotypes with multiple copy
numbers (Simpson’s index, Reciprocal Simpson index, Berger-Parker Dominance index,
and Inverted Berger-Parker Dominance index) and this diversity was more homogenous
between individuals (Buzas and Gibson’s index, Shannon index and Equitability index).
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Table 1. (A), IMN T-cell repertoire; (B) FLC T-cell repertoire.
A: IMN T-cell repertoire
Diversity Metric p Value Log2FC
Biodiversity 0.38 −0.15
Simpson’s index 0.41 −5.45
Dominance index 0.41 0.51
Reciprocal Simpson index 0.75 −0.54
Shannon index 0.39 0.56
Menhinick index 0.37 0.57
Buzas and Gibson’s index 0.35 0.34
Equitability index 0.40 0.43
Berger-Parker Dominance index 0.35 −2.41
Inverted Berger-Parker Dominance index 0.17 1.63
Margalef Richness index 0.38 0.59
Gini coefficient 0.34 −2.46
B: FLC T-cell repertoire
Diversity Metric p Value Log2FC
Biodiversity 0.99 0.00
Simpson’s index 0.73 −0.71
Dominance index 0.73 0.10
Reciprocal Simpson index 0.65 −0.65
Shannon index 0.90 0.05
Menhinick index 0.81 0.10
Buzas and Gibson’s index 0.90 0.06
Equitability index 0.77 0.08
Berger-Parker Dominance index 0.84 −0.24
Inverted Berger-Parker Dominance index 0.56 0.81
Margalef Richness index 0.99 0.01
Gini coefficient 0.92 −0.14
2.8. T-Cells Exhibit Divergent CDR3 Motifs between Auto-Reactive and Allo-Reactive Repertoires
Finally, we examined CDR3 residue composition using software that detects common
CDRR3 motifs from a large database [43] (Figure 7). 118 CDR3 motifs were identified in
the IMN repertoire and variation between the auto-reactive and allo-reactive repertoires
was 84% by two-way ANOVA (p ≤ 0.0001). The allo-reactive repertoire contained more
CDR3 motifs than the auto-reactive repertoire at 93% and 84%, respectively. 124 CDR3
motifs were identified in the IMN repertoire and variation between the auto-reactive and
allo-reactive repertoires was 63% by two-way ANOVA (p ≤ 0.0013). Akin to the IMN
system. The allo-reactive repertoire contained more CDR3 motifs than the auto-reactive
repertoire at 87% and 80%, respectively. Interestingly, the YGQ motif was identified only in
IMN and FLC allo-reactive repertoires. These data show that the TCR repertoires of IMN-
and FLC-specific T-cells show different structural architecture between auto-reactive and
allo-reactive individuals.
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Figure 7. CDR3 motif analysis between auto-reactive and allo-reactive TCRs. (A) IMN and (B) FLC CDR3 loops found by
motif searching. (C) Total percentage of IMN and FLC CDR3 loops found by motif searching. Auto-reactive (green) and
allo-reactive (orange) sequences are shown as are the number of sequences encoding the motif.
3. Discussion
The distinct properties of allo-specific T-cell repertoires are not well known. This study
used dextramers, single-cell TCR analysis and multiple annotation analysis to determine if
alloreactive TCR repertoires could be identified from auto-reactive TCR repertoires. The
enumeration of T-cells from ex vivo blood showed variability between antigens (IMN, FLC,
YLE and KVA), with low mean frequencies, varying from 0.004 to 0.06% of CD8+ T-cells
even among auto-reactive donors. This was expected, as self-specific T-cells are typically
low-frequency, apart from the abnormal MART-1 antigen which can have frequencies up to
0.35% of CD8+ T-cells ex vivo [41], due to a unique germline focused docking mode [44,45].
Importantly, dextramer enumeration across all four antigens showed a consistent difference
in mean frequency when comparing auto-reactive T-cells to allo-reactive T-cells.
Surprisingly, single-cell TCR analysis revealed multiple copies of unique clonotypes
in some allo-reactive populations, suggesting possible cross-reactivity with a pre-existing
memory T-cell response. However, it is unknown if these cells are genuine memory
cells or high-frequency naïve cell clones which bear overproduced TCR from bias in
recombination/selection [15,46–48] or bias in homeostatic proliferation [49]. Also of interest
was the alignment of multiple copy number clonotypes per donor with mean dextramer
frequency hierarchy. For instance, the IMN response showed more donors with multiple
copies of unique clonotypes in the auto-reactive cohort, and the FLC response showed
more donors with multiple copies of unique clonotypes in the allo-reactive cohort. This
aligned with dominance hierarchies from dextramer scanning. However, this correlation
is speculative and requires additional investigation across more donors, antigens, and
alleles. None-the-less, divergent mean T-cell frequencies were consistently observed when
comparing auto-reactive versus allo-reactive individuals.
Gene usage analysis of the IMN and FLC repertoires showed significant differences in
TRBV and TRBJ profiles between cohorts with a consistent preference for TRBJ1-1, TRBV2-1
TRBV2-7 in both allo-reactive systems. Allo-reactive repertoires also showed increased
TRAJ usage in both systems. Additionally, auto-reactive T-cell repertoires exhibited a
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Gaussian distribution in CDR3 length whereas allo-reactive T-cell repertoires exhibited
distorted CDR3 length distribution, with a tendency to encode shorter CDR3 loops. When
examining TRBV/JTRBJ and TRAV/TRAJ pairing between auto-reactive and allo-reactive
repertoires, allo-reactive repertoires showed a much more complex pairing network across
both systems.
Physical-chemical property analysis showed that auto-reactive CDR3 in the IMN sys-
tem were more hydrophobic, which was supported by a corresponding trend in increased
GRAVY scores. This is of interest given hydrophobic CDR3 loops promote the development
of self-reactive T-cells [50] and are enriched in both mouse [50] and human [51] T regulatory
(Treg) cells. This suggests that auto-reactive IMN T-cells may be of the Treg lineage. How-
ever, phenotypic analysis is required to validate this observation. Allo-reactive IMN CDR3
loops showed significant decreases in average Mw and monoisotopic Mw. This made sense
given the IMN repertoire was strongly skewed to short CDR3 sequences previously seen in
gene analysis. The FLC system did not follow this divergence in hydrophobicity and Mw;
however, multivariate analysis of physical-chemical scores could clearly distinguish the
auto-reactive repertoire from the allo-reactive repertoire. Of interest, both IMN and FLC
allo-reactive CDR3 loops showed lower mean theoretical pI scores, meaning allo-reactive
receptors tended to be more acidic in charge.
Diversity metrics of the IMN and FLC systems could clearly distinguish auto-reactive
repertoires from the allo-reactive repertoires in multivariate analysis but trends in univari-
ate analysis. Of note, the same Log2FC patterns were seen in both systems suggesting a
possible general model for allo-reactive repertoires. Here, allo-reactive repertoires showed
a general increase in diversity and consistency between individuals, meaning an increase
in unique clonotypes, fewer unique multiple copy clonotypes and an increase in repertoire
homogeneity between donors.
Motif analysis of CDR3 loops in the IMN and FLC systems could also clearly distin-
guish auto-reactive repertoires from the allo-reactive repertoires on multivariate analysis.
Allo-reactive receptors in both systems showed increased motif pairing, showing that
allo-reactive CDR3 loops exhibit more structural “options” when engaging an allo-reactive
ligand. This finding aligns with increased TCR gene pairing observed in gene analysis and
increased species observation in diversity analysis. While important, it must be said that
these observations are preliminary, correlative and do not infer the cause of graft rejection.
Future studies should be aimed at analysing additional sequences, additional antigens,
additional donors for theory validation and patients for clinical validation.
Using single-cell sequencing, we have defined new auto-reactive and allo-reactive
repertoires for the cancer antigens IMN and FLC, comprising 356 TCRαβ pairs in the
dataset. These receptors can be used for further exploratory research and have translatable
potential. Indeed, foreign-antigen-specific TCR show up to a 10,000-fold increase in affinity
compared with self-antigen-specific TCR [52] and are in the range of pathogen-specific
TCRs (KD = 0.1–10 µM) [53] which can bypass coreceptor help [54] and initiate cell death
within five minutes [55]. Thus, the allo-reactive TCR identified here could apply to TCR
gene transfer and adoptive cell therapy. Other potential therapies include “swapping” the
allo-reactive peptide with an antagonist to prevent alloreactivity [54] or enhancing the
affinity of the auto-reactive or allo-reactive TCR further using phage display [55]. These
affinity enhanced receptors can be used as soluble drugs and are currently in clinical
trials [56].
However, these receptors require functional validation before proceeding. Neverthe-
less, we are optimistic as the method used here has been published by our team numerous
times, including functional validation in cancer-, Epstein-Barr virus-, cytomegalovirus- [39]
and influenza-specific systems [57–59].
There are other variables to consider before TCR therapy, including “personal genetics”
and “infectious history” which likely influence our personal T-cell repertoire makeup.
Any two individuals can differ by up to 800 million single nucleotide polymorphisms
(SNPs) between genomes [60]. This is termed personal genetics, and we currently do not
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understand how our personal genomes fully impact immune function. Another variable
is our infectivity record which is defined by which pathogens we acquire over the course
of life and at what age, termed our infectious history [61], which can impact on future
immune challenges.
In summary, we show allo-reactive T-cell repertoires and be defined from auto-reactive
repertoires through differences in enumeration and TCR architecture when examining gene
usage, gene pairing, CDR3 length, CDR3 physical-chemical properties, diversity measures
and CDR3 motif appearance and usage. These data increase the knowledge base of the
mechanisms underlying T-cell alloreactivity and may lead to new adoptive therapies, TCR
therapies and the rational design of TCR for therapeutic use in autoimmunity, infectious
disease, and cancer.
4. Materials and Methods
4.1. Sample Preparation and Processing
Healthy donor blood was studied using protocols carried out in accordance with
guidelines and regulations under QIMR Berghofer Medical Research Institute (QIMRB)
(HREC P2058, approved 4/9/2014). Informed consent was obtained from all partici-
pants in the study. The study was performed according to the rules of the Declaration
of Helsinki of 1975. Peripheral blood mononuclear cells were separated, as previously
described [62]. Briefly, peripheral blood mononuclear cells (PBMCs) were isolated by
Ficoll-Paque PLUS (GE Healthcare, Chicago, IL, USA) density gradient centrifugation and
cryopreserved in R10 medium (RPMI-1640 containing 10% FCS) supplemented with 10%
DMSO (Sigma-Aldrich, St. Louis, MO, USA). PBMC were stored at 106 cells in a 1 mL vial
and cryopreserved for batch analysis, which we have found increases the sensitivity of
gene and protein detection and decreases experimental artefact. Eight-digit HLA typing
was performed using NGS by BGI Genomics (BGI, Shanghai, China).
4.2. Flow Cytometry and Single-Cell Sorting
Cryopreserved PBMC were thawed in 37 ◦C R10 media with 1 uL/mL of DNAse
1 (Thermo Fisher Scientific, Waltham, MA, USA) and 0.3 nM of dasatinib (Axon Med-
chem, Reston, VA, USA). APC-conjugated dextramer was added for 30 min on ice us-
ing either HLA-0201-IMNDMPIYM-APC (IMN), HLA-0201-FLCMKALLL-APC (FLC),
HLA-A0201-KVAELVHFL-APC (KVA) or HLA-A0201-YLEPGPVTV-APC (YLE) dextramer
(Immunodex, Toronto, ON, USA). We next surface stained the cells with CD14-Pacific Blue,
CD16-Pacific Blue, CD19-Pacific blue (all BioLegend, San Diego, CA, USA), LIVE/DEAD®
Fixable Aqua (Life Technologies, Carlsbad, CA, USA), CD3-PE and CD8-FITC (all Bi-
oLegend, San Diego, CA, USA) and sorting was performed as previously described [10].
Single cells were gated using FSC-W and FSC-H. Non-viable cells were dumped using
LIVE/DEAD and CD14, CD16 and CD19. Dextramer+ cells were sorted twice at low flow
rates on a FACSAria IIu sorter (BD, Franklin Lakes, NJ, USA) into chilled 96-well twin-tec
PCR plates (Eppendorf, Hamburg, Germany). The cells were then centrifuged at 500× g
for 2 min and immediately stored at −80 ◦C.
4.3. Single-Cell TCRαβ Amplification and Annotation
As previously described [63], cDNA was generated using VILO (Thermo Fisher,
Waltham, MA, USA) according to the manufactures’ protocol. A PCR was then performed
to amplify the TCR locus followed by a then a nested PCR. Gels were run to confirm
the amplification of positive products and cleaned for Sanger sequencing using QIAGEN
plates (QIAGEN, Hilden, Germany). Post sequencing, TCRα and TCRβ transcripts were
annotated using Bioedit and V-QUEST [64]. Random sampling and percentage usage
graphs were generated in Excel 365 (Microsoft, 2019). Chord diagrams were generated in R
using the circlize package [65]. CDR3 motifs were determined using GLIPH 2.0 [43]. Paired
clones are listed in Supplementary Tables S1–S4.
Int. J. Mol. Sci. 2021, 22, 1625 13 of 16
4.4. Diversity Analysis
T-cell repertoire diversity metrics were determined from total counts from individual
donors. The calculations comprise:
4.5. Physical-Chemical Properties
CDR3 loop hydrophobicity, GRAVY, average Mw, monoisotopic Mw and theoretical pI
were determined using the Proteotypic Peptide Analyzing Tool (Thermo Fisher Scientific,
Waltham, MA, USA).
4.6. Statistical Analysis
TCR repertoire annotation was performed using IMGT/V-QUEST [64] and Excel 365
(Microsoft, USA). Post TCR gene alignment and CDR3 annotation, repertoires were then
binned into individual dextramer+ repertoires or total pooled repertoires. Depending on the
analysis, clonotypes were assigned to total repertoires (auto-reactive versus allo-reactive),
abundance repertoires (where multiple clonal sequences were included) and appearance
repertoires (where clonal sequences were decreased to one count and clonotypes randomly
selected). Data was first checked for normality and lognormality using the D’Agostino-
Pearson omnibus normality test and or the Shapiro-Wilk normality test. If the data failed
these tests, a one sample t-test was performed with a Wilcoxon signed-rank test with mean
calculated. Post quality control, a Mann-Whitney rank test, two-way ANOVA with Tukey’s
multiple comparison test was performed using Prism V9.01 (Graphpad, USA). The p-value
cut-offs are defined by * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Supplementary Materials: The following are available online at https://www.mdpi.com/1422-006
7/22/4/1625/s1.
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TCR T-cell receptor
MHC Major histocompatibility complex
HLA Human leukocyte antigen complex
p Peptide within the MHC/HLA binding grove
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